Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven F Powell

Showing results (1-10 of 22) with videos related to

Pageof 3
Sort By:
Current Treatment Options in Neurology|September 16, 2010
Treatment of melanoma-associated retinopathySteven F Powell, Arkadiusz Z Dudek
Pharmacogenomics and Personalized Medicine|December 11, 2012
Tailoring treatment of nonsmall cell lung cancer by tissue type: role of pemetrexedSteven F Powell, Arkadiusz Z Dudek
Cancers|October 23, 2021
The Key Differences between Human Papillomavirus-Positive and -Negative Head and Neck Cancers: Biological and Clinical ImplicationsSteven F Powell, Lexi Vu, William C Spanos, et al.
Clinical Lung Cancer|July 3, 2013
Phase II study of topotecan and bevacizumab in advanced, refractory non--small-cell lung cancerSteven F Powell, Amer Beitinjaneh, Mathewos Tessema, et al.
Cancers|May 28, 2022
Characterization of the Immune Response to PD-1 Blockade during Chemoradiotherapy for Head and Neck Squamous Cell CarcinomaJuan L Callejas-Valera, Daniel W Vermeer, Christopher T Lucido, et al.
The New England Journal of Medicine|July 14, 2016
Olanzapine for the Prevention of Chemotherapy-Induced Nausea and VomitingRudolph M Navari, Rui Qin, Kathryn J Ruddy, et al.
Journal for Immunotherapy of Cancer|December 6, 2019
A phase Ib study of utomilumab (PF-05082566) in combination with mogamulizumab in patients with advanced solid tumorsEzra E W Cohen, Michael J Pishvaian, Dale R Shepard, et al.
Cancer Research Communications|June 22, 2026
Phase 1 study of oncolytic virus VV1 as monotherapy or in combination with avelumab in patients with relapsed refractory solid tumorsJaime R Merchan, Manish R Patel, Timothy P Cripe, et al.
Oncology and Therapy|June 11, 2025
Impact of Tumor Response and Response Duration on Survival Among Participants Receiving Pembrolizumab Plus Chemotherapy as First-Line Therapy for Non-Small-Cell Lung CancerMarina C Garassino, Ying Cheng, Delvys Rodriguez-Abreu, et al.
Lung Cancer (Amsterdam, Netherlands)|March 20, 2019
Pembrolizumab in combination with ipilimumab as second-line or later therapy for advanced non-small-cell lung cancer: KEYNOTE-021 cohorts D and HMatthew A Gubens, Lecia V Sequist, James P Stevenson, et al.
Pageof 3

Showing results (1-10 of 22) with videos related to

Sort By:
Pageof 3
Current Treatment Options in Neurology|September 16, 2010
Treatment of melanoma-associated retinopathySteven F Powell, Arkadiusz Z Dudek
Pharmacogenomics and Personalized Medicine|December 11, 2012
Tailoring treatment of nonsmall cell lung cancer by tissue type: role of pemetrexedSteven F Powell, Arkadiusz Z Dudek
Cancers|October 23, 2021
The Key Differences between Human Papillomavirus-Positive and -Negative Head and Neck Cancers: Biological and Clinical ImplicationsSteven F Powell, Lexi Vu, William C Spanos, et al.
Clinical Lung Cancer|July 3, 2013
Phase II study of topotecan and bevacizumab in advanced, refractory non--small-cell lung cancerSteven F Powell, Amer Beitinjaneh, Mathewos Tessema, et al.
Cancers|May 28, 2022
Characterization of the Immune Response to PD-1 Blockade during Chemoradiotherapy for Head and Neck Squamous Cell CarcinomaJuan L Callejas-Valera, Daniel W Vermeer, Christopher T Lucido, et al.
The New England Journal of Medicine|July 14, 2016
Olanzapine for the Prevention of Chemotherapy-Induced Nausea and VomitingRudolph M Navari, Rui Qin, Kathryn J Ruddy, et al.
Journal for Immunotherapy of Cancer|December 6, 2019
A phase Ib study of utomilumab (PF-05082566) in combination with mogamulizumab in patients with advanced solid tumorsEzra E W Cohen, Michael J Pishvaian, Dale R Shepard, et al.
Cancer Research Communications|June 22, 2026
Phase 1 study of oncolytic virus VV1 as monotherapy or in combination with avelumab in patients with relapsed refractory solid tumorsJaime R Merchan, Manish R Patel, Timothy P Cripe, et al.
Oncology and Therapy|June 11, 2025
Impact of Tumor Response and Response Duration on Survival Among Participants Receiving Pembrolizumab Plus Chemotherapy as First-Line Therapy for Non-Small-Cell Lung CancerMarina C Garassino, Ying Cheng, Delvys Rodriguez-Abreu, et al.
Lung Cancer (Amsterdam, Netherlands)|March 20, 2019
Pembrolizumab in combination with ipilimumab as second-line or later therapy for advanced non-small-cell lung cancer: KEYNOTE-021 cohorts D and HMatthew A Gubens, Lecia V Sequist, James P Stevenson, et al.
Pageof 3